Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients
Background: Hepatocellular carcinoma (HCC) is a multistage process resulting from various genetic changes. We aimed to determine nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 expression and to evaluate their importance in HCC diagnosis. Methods: One hundred and twenty chronic hepatiti...
Gespeichert in:
| Veröffentlicht in: | British journal of biomedical science 2017-10, Vol.74 (4), p.170-175 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 175 |
|---|---|
| container_issue | 4 |
| container_start_page | 170 |
| container_title | British journal of biomedical science |
| container_volume | 74 |
| creator | Attallah, AM El-Far, M Abdelrazek, MA Omran, MM Attallah, AA Elkhouly, AA Elkenawy, HM Farid, K |
| description | Background: Hepatocellular carcinoma (HCC) is a multistage process resulting from various genetic changes. We aimed to determine nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 expression and to evaluate their importance in HCC diagnosis.
Methods: One hundred and twenty chronic hepatitis C (CHC) patients (60 non-HCC CHC patients and 60 HCC patients who had a single small ( |
| doi_str_mv | 10.1080/09674845.2017.1334739 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_09674845_2017_1334739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1920201807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-ff2c4b8c16bfaad222657843e18db5f9d45d9a9642421446ed4aba402883bdc83</originalsourceid><addsrcrecordid>eNp9kctu1DAYhS1ERYfCI4AssWGTwXZ8yw404ia16gbWluMLcUnsYCdC8zB9VxzNtAuQWFj24jvH_38OAK8w2mMk0TvUcUElZXuCsNjjtqWi7Z6AHaGCNkh2_CnYbUyzQZfgeSl3COGOCP4MXBIpEEOM78D9IU19iM7CtTiYPIyrGZ3OcB5SqWfOaXEhQtPcHA3U0ULjxnEd_yVm1kKfMhzcrJf0SBmdTYhp0tC6xZklpAgrPYQfQ5ND-QnNkFMM5qQLSyjwALeXi0t5AS68Hot7eb6vwPdPH78dvjTXt5-_Hj5cN4ZytDTeE0N7aTDvvdaWEMKZkLR1WNqe-c5SZjvdcUoowZRyZ6nuNUVEyra3RrZX4O3Jty7za3VlUVMo2wo6urQWVXNDNWeJREXf_IXepTXHOp0iuKOoFZRthuxEmZxKyc6rOYdJ56PCSG39qYf-1NafOvdXda_P7ms_OfuoeiisAu9PQIg17En_Tnm0atHHMWWfdTShqPb_f_wB88isqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2194037458</pqid></control><display><type>article</type><title>Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Attallah, AM ; El-Far, M ; Abdelrazek, MA ; Omran, MM ; Attallah, AA ; Elkhouly, AA ; Elkenawy, HM ; Farid, K</creator><creatorcontrib>Attallah, AM ; El-Far, M ; Abdelrazek, MA ; Omran, MM ; Attallah, AA ; Elkhouly, AA ; Elkenawy, HM ; Farid, K</creatorcontrib><description>Background: Hepatocellular carcinoma (HCC) is a multistage process resulting from various genetic changes. We aimed to determine nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 expression and to evaluate their importance in HCC diagnosis.
Methods: One hundred and twenty chronic hepatitis C (CHC) patients (60 non-HCC CHC patients and 60 HCC patients who had a single small (<5 cm) tumour) were recruited. The gene products of c-Myc and p53 were identified in liver tissues and serum samples using immunostaining, western blot and ELISA.
Results: Immunohistochemical detection of c-Myc and p53 with monospecific antibodies revealed intense and diffuse cytoplasmic staining patterns. Accumulated mutant proteins, released from tumour cells into the extracellular serum, were detected at 62 KDa, for c-Myc, and 53 KDa, for p53, using western blotting. In contrast to alpha feto-protein, there was a significant increase (p < 0.0001) in the positivity rate of c-Myc (86.7% vs. 6.7%) and p53 (78.3% vs. 8.3%) in the malignant vs. non-malignant patients. The parallel combination of c-Myc and p53 reach the absolute sensitivity (100%), for more accurate and reliable HCC detection (specificity was 87%).
Conclusion: c-Myc and p53 are potential HCC diagnostic biomarkers, and convenient combinations of them could improve diagnostic accuracy of HCC.</description><identifier>ISSN: 0967-4845</identifier><identifier>EISSN: 2474-0896</identifier><identifier>DOI: 10.1080/09674845.2017.1334739</identifier><identifier>PMID: 28705056</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>biomarkers ; c-Myc ; c-Myc protein ; Enzyme-linked immunosorbent assay ; Hepatitis ; Hepatitis C ; Hepatocellular carcinoma ; Interferon ; Liver cancer ; Myc protein ; p53 Protein ; serum ; Tumors ; Western blotting</subject><ispartof>British journal of biomedical science, 2017-10, Vol.74 (4), p.170-175</ispartof><rights>2017 British Journal of Biomedical Science 2017</rights><rights>2017 British Journal of Biomedical Science</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-ff2c4b8c16bfaad222657843e18db5f9d45d9a9642421446ed4aba402883bdc83</citedby><cites>FETCH-LOGICAL-c460t-ff2c4b8c16bfaad222657843e18db5f9d45d9a9642421446ed4aba402883bdc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28705056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Attallah, AM</creatorcontrib><creatorcontrib>El-Far, M</creatorcontrib><creatorcontrib>Abdelrazek, MA</creatorcontrib><creatorcontrib>Omran, MM</creatorcontrib><creatorcontrib>Attallah, AA</creatorcontrib><creatorcontrib>Elkhouly, AA</creatorcontrib><creatorcontrib>Elkenawy, HM</creatorcontrib><creatorcontrib>Farid, K</creatorcontrib><title>Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients</title><title>British journal of biomedical science</title><addtitle>Br J Biomed Sci</addtitle><description>Background: Hepatocellular carcinoma (HCC) is a multistage process resulting from various genetic changes. We aimed to determine nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 expression and to evaluate their importance in HCC diagnosis.
Methods: One hundred and twenty chronic hepatitis C (CHC) patients (60 non-HCC CHC patients and 60 HCC patients who had a single small (<5 cm) tumour) were recruited. The gene products of c-Myc and p53 were identified in liver tissues and serum samples using immunostaining, western blot and ELISA.
Results: Immunohistochemical detection of c-Myc and p53 with monospecific antibodies revealed intense and diffuse cytoplasmic staining patterns. Accumulated mutant proteins, released from tumour cells into the extracellular serum, were detected at 62 KDa, for c-Myc, and 53 KDa, for p53, using western blotting. In contrast to alpha feto-protein, there was a significant increase (p < 0.0001) in the positivity rate of c-Myc (86.7% vs. 6.7%) and p53 (78.3% vs. 8.3%) in the malignant vs. non-malignant patients. The parallel combination of c-Myc and p53 reach the absolute sensitivity (100%), for more accurate and reliable HCC detection (specificity was 87%).
Conclusion: c-Myc and p53 are potential HCC diagnostic biomarkers, and convenient combinations of them could improve diagnostic accuracy of HCC.</description><subject>biomarkers</subject><subject>c-Myc</subject><subject>c-Myc protein</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatocellular carcinoma</subject><subject>Interferon</subject><subject>Liver cancer</subject><subject>Myc protein</subject><subject>p53 Protein</subject><subject>serum</subject><subject>Tumors</subject><subject>Western blotting</subject><issn>0967-4845</issn><issn>2474-0896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1DAYhS1ERYfCI4AssWGTwXZ8yw404ia16gbWluMLcUnsYCdC8zB9VxzNtAuQWFj24jvH_38OAK8w2mMk0TvUcUElZXuCsNjjtqWi7Z6AHaGCNkh2_CnYbUyzQZfgeSl3COGOCP4MXBIpEEOM78D9IU19iM7CtTiYPIyrGZ3OcB5SqWfOaXEhQtPcHA3U0ULjxnEd_yVm1kKfMhzcrJf0SBmdTYhp0tC6xZklpAgrPYQfQ5ND-QnNkFMM5qQLSyjwALeXi0t5AS68Hot7eb6vwPdPH78dvjTXt5-_Hj5cN4ZytDTeE0N7aTDvvdaWEMKZkLR1WNqe-c5SZjvdcUoowZRyZ6nuNUVEyra3RrZX4O3Jty7za3VlUVMo2wo6urQWVXNDNWeJREXf_IXepTXHOp0iuKOoFZRthuxEmZxKyc6rOYdJ56PCSG39qYf-1NafOvdXda_P7ms_OfuoeiisAu9PQIg17En_Tnm0atHHMWWfdTShqPb_f_wB88isqA</recordid><startdate>20171002</startdate><enddate>20171002</enddate><creator>Attallah, AM</creator><creator>El-Far, M</creator><creator>Abdelrazek, MA</creator><creator>Omran, MM</creator><creator>Attallah, AA</creator><creator>Elkhouly, AA</creator><creator>Elkenawy, HM</creator><creator>Farid, K</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20171002</creationdate><title>Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients</title><author>Attallah, AM ; El-Far, M ; Abdelrazek, MA ; Omran, MM ; Attallah, AA ; Elkhouly, AA ; Elkenawy, HM ; Farid, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-ff2c4b8c16bfaad222657843e18db5f9d45d9a9642421446ed4aba402883bdc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>biomarkers</topic><topic>c-Myc</topic><topic>c-Myc protein</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatocellular carcinoma</topic><topic>Interferon</topic><topic>Liver cancer</topic><topic>Myc protein</topic><topic>p53 Protein</topic><topic>serum</topic><topic>Tumors</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Attallah, AM</creatorcontrib><creatorcontrib>El-Far, M</creatorcontrib><creatorcontrib>Abdelrazek, MA</creatorcontrib><creatorcontrib>Omran, MM</creatorcontrib><creatorcontrib>Attallah, AA</creatorcontrib><creatorcontrib>Elkhouly, AA</creatorcontrib><creatorcontrib>Elkenawy, HM</creatorcontrib><creatorcontrib>Farid, K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of biomedical science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Attallah, AM</au><au>El-Far, M</au><au>Abdelrazek, MA</au><au>Omran, MM</au><au>Attallah, AA</au><au>Elkhouly, AA</au><au>Elkenawy, HM</au><au>Farid, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients</atitle><jtitle>British journal of biomedical science</jtitle><addtitle>Br J Biomed Sci</addtitle><date>2017-10-02</date><risdate>2017</risdate><volume>74</volume><issue>4</issue><spage>170</spage><epage>175</epage><pages>170-175</pages><issn>0967-4845</issn><eissn>2474-0896</eissn><abstract>Background: Hepatocellular carcinoma (HCC) is a multistage process resulting from various genetic changes. We aimed to determine nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 expression and to evaluate their importance in HCC diagnosis.
Methods: One hundred and twenty chronic hepatitis C (CHC) patients (60 non-HCC CHC patients and 60 HCC patients who had a single small (<5 cm) tumour) were recruited. The gene products of c-Myc and p53 were identified in liver tissues and serum samples using immunostaining, western blot and ELISA.
Results: Immunohistochemical detection of c-Myc and p53 with monospecific antibodies revealed intense and diffuse cytoplasmic staining patterns. Accumulated mutant proteins, released from tumour cells into the extracellular serum, were detected at 62 KDa, for c-Myc, and 53 KDa, for p53, using western blotting. In contrast to alpha feto-protein, there was a significant increase (p < 0.0001) in the positivity rate of c-Myc (86.7% vs. 6.7%) and p53 (78.3% vs. 8.3%) in the malignant vs. non-malignant patients. The parallel combination of c-Myc and p53 reach the absolute sensitivity (100%), for more accurate and reliable HCC detection (specificity was 87%).
Conclusion: c-Myc and p53 are potential HCC diagnostic biomarkers, and convenient combinations of them could improve diagnostic accuracy of HCC.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>28705056</pmid><doi>10.1080/09674845.2017.1334739</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0967-4845 |
| ispartof | British journal of biomedical science, 2017-10, Vol.74 (4), p.170-175 |
| issn | 0967-4845 2474-0896 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_09674845_2017_1334739 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | biomarkers c-Myc c-Myc protein Enzyme-linked immunosorbent assay Hepatitis Hepatitis C Hepatocellular carcinoma Interferon Liver cancer Myc protein p53 Protein serum Tumors Western blotting |
| title | Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T00%3A41%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20use%20of%20nuclear%20phosphoprotein%20c-Myc%20and%20cellular%20phosphoprotein%20p53%20for%20hepatocellular%20carcinoma%20detection%20in%20high-risk%20chronic%20hepatitis%20C%20patients&rft.jtitle=British%20journal%20of%20biomedical%20science&rft.au=Attallah,%20AM&rft.date=2017-10-02&rft.volume=74&rft.issue=4&rft.spage=170&rft.epage=175&rft.pages=170-175&rft.issn=0967-4845&rft.eissn=2474-0896&rft_id=info:doi/10.1080/09674845.2017.1334739&rft_dat=%3Cproquest_cross%3E1920201807%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2194037458&rft_id=info:pmid/28705056&rfr_iscdi=true |